Patients with KRAS wild-type tumours were randomised @:@ to afatinib ( @ mg/day , increasing to @ mg/day if minimal toxicity ) or cetuximab weekly ( @ mg/m@ loading dose , then @ mg/m@/week ) according to number of previous chemotherapy lines .